Clinical and Genomic Factors Associated with Elacestrant Outcomes in <i>ESR1-</i> Mutant Metastatic Breast Cancer
In ESR1-mutant MBC, elacestrant treatment durations support the routine use of elacestrant monotherapy in appropriately selected patients. For patients with concurrent ESR1 and PI3K pathway mutations, single-agent activity was comparable with outcomes observed in phase III studies. See related article by Rugo et al., p. 179.
Authors
- Azka Ali (ORCID: https://orcid.org/0000-0001-7476-6664)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- Sheila Solomon (ORCID: https://orcid.org/0000-0002-3882-588X)
- Marla Lipsyc-Sharf (ORCID: https://orcid.org/0000-0002-4071-6383)
- Seth A. Wander (ORCID: https://orcid.org/0000-0002-4127-4708)
- Aditya Bardia (ORCID: https://orcid.org/0000-0003-4885-1157)
- Adam Brufsky (ORCID: https://orcid.org/0000-0001-8080-7960)
- Kevin Kalinsky (ORCID: https://orcid.org/0000-0002-3113-7902)
- Jayati Saha (ORCID: https://orcid.org/0000-0003-2613-9441)
- Maxwell R. Lloyd (ORCID: https://orcid.org/0000-0001-9810-0437)
- Nicole Zhang (ORCID: https://orcid.org/0009-0001-2706-5838)
- Caroline Weipert (ORCID: https://orcid.org/0000-0002-0069-882X)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Cleveland Clinic (US)
- Emory University (US)
- University of California, Los Angeles (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Guardant (United States) (US)
- Sarah Cannon (US)
- Comprehensive Blood & Cancer Center (US)
- University of Colorado Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Tennessee Oncology (US)
- Center for Cancer Research (US)
- UCLA Jonsson Comprehensive Cancer Center
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3033
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Gilead Sciences